<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>L-DOPA</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01235</strong>&#160; (APRD00309, EXPT01107)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>The naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01235/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01235/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01235.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01235.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01235.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01235.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01235.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01235">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(&#8722;)-3-(3,4-dihydroxyphenyl)-L-alanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(&#8722;)-dopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>3-Hydroxy-L-tyrosine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dihydroxy-L-phenylalanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>L-3,4-dihydroxyphenylalanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>L-beta-(3,4-Dihydroxyphenyl)alanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>L-DOPA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>&#946;-(3,4-dihydroxyphenyl)alanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Bidopal</td><td>GlaxoSmithKline</td></tr><tr><td>Dopar</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Doparl</td><td>Kyowa Hakko Kirin</td></tr><tr><td>Dopasol</td><td>Daiichi Sankyo</td></tr><tr><td>Dopaston</td><td>Ohara Yakuhin</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Atamet</td><td>carbidopa + levodopa</td></tr><tr><td>Duodopa</td><td>Levodopa and Carbidopa</td></tr><tr><td>Madopar</td><td>Levodopa and Benserazide</td></tr><tr><td>Menkart</td><td>Levodopa and Benserazide</td></tr><tr><td>Parcopa</td><td>Carbidopa + L-DOPA</td></tr><tr><td>Prolopa</td><td>benserazide + levodopa</td></tr><tr><td>Sinemet</td><td>carbidopa + levodopa</td></tr><tr><td>Sinemet CR</td><td>Levodopa and Carbidopa</td></tr><tr><td>Stalevo</td><td>carbidopa + levodopa + entacapone</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/dopamine-agents">Dopamine Agents</a></li>
<li><a href="/mesh/antiparkinson-agents">Antiparkinson Agents</a></li>
<li><a href="/mesh/antidyskinetics">Antidyskinetics</a></li></ul></td></tr><tr><th>CAS number</th><td>59-92-7</td></tr><tr><th>Weight</th><td>Average: 197.1879<br>Monoisotopic: 197.068807845</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>11</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>WTDRDQBEARUVNC-LURJTMIESA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01235.gif?1265922771">show</a>(7.19 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenols and Derivatives</td></tr><tr><th>Direct parent</th><td>Catecholamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Phenylpropanoic Acids; Alpha Amino Acids and Derivatives; Amphetamines and Derivatives; Amino Fatty Acids; Polyols; Enolates; Carboxylic Acids; Polyamines; Enols; Monoalkylamines</td></tr><tr><th>Substituents</th><td>polyol; carboxylic acid; enolate; enol; polyamine; carboxylic acid derivative; amine; primary amine; primary aliphatic amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication.</td></tr><tr><th>Pharmacodynamics</th><td>Levodopa (L-dopa) is used to replace dopamine lost in Parkinson's disease because dopamine itself cannot cross the blood-brain barrier where its precursor can. However, L-DOPA is converted to dopamine in the periphery as well as in the CNS, so it is administered with a peripheral DDC (dopamine decarboxylase) inhibitor such as carbidopa, without which 90% is metabolised in the gut wall, and with a COMT inhibitor if possible; this prevents about a 5% loss. The form given therapeutically is therefore a prodrug which avoids decarboxylation in the stomach and periphery, can cross the blood-brain barrier, and once in the brain is converted to the neurotransmitter dopamine by the enzyme aromatic-L-amino-acid decarboxylase.</td></tr><tr><th>Mechanism of action</th><td>Striatal dopamine levels in symptomatic Parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine.</td></tr><tr><th>Absorption</th><td>Levodopa is rapidly absorbed from the proximal small intestine by the large neutral amino acid (LNAA) transport carrier system.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>High</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>95% of an administered oral dose of levodopa is pre-systemically decarboxylated to dopamine by the L-aromatic amino acid decarboxylase (AAAD) enzyme in the stomach, lumen of the intestine, kidney, and liver. Levodopa also may be methoxylated by the hepatic catechol-O-methyltransferase (COMT) enzyme system to 3-O-methyldopa (3-OMD), which cannot be converted to central dopamine.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>L-DOPA</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00548">DOPA sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/566">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>50 to 90 minutes</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 2363 mg/kg; Oral, rabbit: LD<sub>50</sub> = 609 mg/kg; Oral, rat: LD<sub>50</sub> = 1780 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Disulfiram Action Pathway</td><td>Drug action</td></tr><tr><td>Alkaptonuria</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00169?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00169</a></td></tr><tr><td>Aromatic L-Aminoacid Decarboxylase Deficiency</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00170?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00170</a></td></tr><tr><td>Dopamine beta-hydroxylase deficiency</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00498?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00498</a></td></tr><tr><td>Catecholamine Biosynthesis</td><td>Metabolic</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00012?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00012</a></td></tr><tr><td>Monoamine oxidase-a deficiency (MAO-A)</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00533?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00533</a></td></tr><tr><td>Tyrosine hydroxylase deficiency</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00497?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00497</a></td></tr><tr><td>Hawkinsinuria</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00190?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00190</a></td></tr><tr><td>Tyrosinemia Type I</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00218?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00218</a></td></tr><tr><td>Tyrosine Metabolism</td><td>Metabolic</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00006?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00006</a></td></tr><tr><td>Tyrosinemia, transient, of the newborn</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00494?highlight%5Bcompounds%5D%5B%5D=DB01235&amp;highlight%5Bproteins%5D%5B%5D=DB01235">SMP00494</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8715</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9264</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5734</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.989</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.988</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9211</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8236</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8514</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7117</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9467</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9765</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9576</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9504</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.914</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9713</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9106
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.941
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.7332
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0131 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9872
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9524
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Shire development inc</li>
<li>Hoffmann la roche inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.azurpharma.com">AzurPharma Inc.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.cimalabs.com">Cima Laboratories Inc.</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.endo.com">Endo Pharmaceuticals Inc.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.orionpharma.com">Orion Corporation</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1149">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/286">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/287">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/288">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3387">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3388">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3389">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3390">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3391">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3392">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3393">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3394">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3395">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3396">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3397">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3398">MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1190">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of levodopa</td></tr><tr><td><a href="/drugs/DB00893">Iron Dextran</a></td><td>Iron decreases the absorption of dopa derivatives</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Methyldopa increases the effect and toxicity of levodopa</td></tr><tr><td><a href="/drugs/DB01233">Metoclopramide</a></td><td>Levodopa decreases the effect of metoclopramide</td></tr><tr><td><a href="/drugs/DB01267">Paliperidone</a></td><td>The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, levodopa. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. </td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of levodopa</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Tetrabenazine may cause Parkinsonian symptoms and neutralize the effect of Levodopa.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Levodopa. Consider alternate therapy or monitor for decreased effects of both agents. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Levodopa may increase the adverse effects of Tranylcypromine. Risk of severe hypertension. Concomitant therapy should be avoided or monitored closely for adverse effects of Tranylcypromine. </td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>